查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1914572

基因改造動物市場－全球產業規模、佔有率、趨勢、機會和預測：按產品、PCR、技術、應用、模式生物、最終用戶、地區和競爭格局分類，2021-2031年

Transgenic Animal Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By PCR, By Technique, By Application, By Model Organisms, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球基因改造動物市場預計將從2025年的41.8億美元成長到2031年的76.3億美元，複合年成長率（CAGR）為10.55%。該行業涉及將基因經過人為改造以表達特定所需性狀的生物體商業化和應用，用於研究和生物生產。推動這一成長的關鍵因素包括：對用於研究人類慢性疾病的預測性動物模型的需求日益成長，以及生物製藥領域對重組蛋白和單株抗體的需求不斷增加。此外，基因編輯技術的持續進步也成為重要的成長引擎，使得人們能夠精確地建立能夠重現複雜生理狀態的動物模型，而這些複雜生理狀態對於可靠的藥物發現和開發至關重要。

市場概覽
預測期 2027-2031
市場規模：2025年 41.8億美元
市場規模：2031年 76.3億美元
複合年成長率：2026-2031年 10.55%
成長最快的細分市場 基因癌症
最大的市場 北美洲

儘管存在這些有利因素，但由於嚴格的倫理法規和公眾對動物福利日益成長的關注，市場仍面臨著許多障礙，這可能導致監管核准延遲並增加遵循成本。然而，科學界仍高度依賴這些模型進行重要研究。 2024 年《了解動物研究》報告的數據顯示，英國45% 的受監管科學程序都用於創造或培育基因改造動物，凸顯了該領域在生物醫學創新中持續且重要的作用。

市場促進因素

基因組編輯和基因工程技術的突破性進展是全球基因改造動物市場的主要驅動力。 CRISPR-Cas9等精準工具的整合徹底改變了我們對動物進行特定基因改造的能力，使得培育具有與人類相容的器官和精準疾病表現型的生物體成為可能。這項技術的成熟吸引了大量投資，尤其是在異種移植應用領域，基因改造豬是可行的器官來源。例如，eGenesis公司於2024年9月宣布已獲得1.91億美元的D輪資金籌措，用於推進其基因工程豬腎候選藥物進入首次人體臨床試驗，充分展現了市場對這些基因組平台的強大商業性信心。

同時，對預測性臨床前人類疾病模型日益成長的需求正顯著推動市場發展。隨著複雜慢性疾病的增多，製藥研發人員需要先進的體內系統來篩檢潛在治療方法，並避免後期臨床試驗失敗。 2024年1月，美國癌症協會（ACS）發布的《2024年癌症事實與數據》報告預測，美國新增癌症病例數將首次超過200萬例，凸顯了對先進癌症模型的迫切需求。這種疾病負擔正促使大量資金投入利用基因改造生物的藥物研發管線。例如，默克在2024年2月報告稱，其2023年全年研發總支出將達到305億美元，這反映了對生物醫學創新的大力支持。

市場挑戰

全球基因改造動物市場成長的主要障礙在於嚴格的倫理法規以及公眾對動物福利日益成長的關注。世界各地的監管機構正在推出更嚴格的標準，要求相關機構接受全面的倫理審查，並嚴格遵守替代、減少和最佳化原則。這些合規要求需要在監測和記錄方面投入大量資金，導致研發週期延長、營運成本增加，最終阻礙了動物實驗的擴展，並促進了非動物替代方法的應用。

這些法規的具體影響在近期營運數據中顯而易見，數據顯示基因改造模型的使用量下降。根據《動物研究概論》（Understanding Animal Research）報道，2024年英國涉及基因改造動物的創建和繁殖的程序數量比去年同期下降了0.5%。這一下降與監管壓力增加和市場活動放緩密切相關，因為研究機構和製藥公司由於倫理和行政負擔日益加重，被迫減少對這些複雜生物模型的依賴。

市場趨勢

重塑基因改造動物市場的一項根本性轉變是將模型建構工作策略性外包（外包給合約研究組織CRO）。製藥公司正加速放棄資本密集的內部育種項目，以減輕維護設施和遵守法規相關的高昂固定成本。這種轉變使藥物研發人員能夠將固定成本轉化為可變支出，同時也能獲得擁有複雜飼養管理的專業動物族群。這種營運模式轉變帶來的財務影響在近期主要服務供應商的業績中清晰可見。 2024年11月，查爾斯河實驗室公佈第三季財報，其研究模型服務部門的營收成長5.9%，達到1.978億美元，顯示該產業對外部合作夥伴的依賴程度日益加深。

同時，專門用於評估複雜免疫療法的腫瘤人源化免疫模型正迅速拓展市場。與傳統的基因改造生物不同，這些專用平台經過基因工程改造，能夠攜帶功能性的人類免疫系統，使研究人員能夠在全身環境下檢驗查核點抑制劑和抗體藥物複合體的療效。這一趨勢區別於一般疾病模型，其重點在於精確地在動物宿主體內重建人類免疫反應，旨在降低轉化研究的失敗率。 Champions Oncology 等公司推動了這一細分市場的商業性擴張。該公司在 2024 年 12 月公佈的 2025 會計年度第二季財報中顯示，其營收成長了 17%，達到 1,350 萬美元，這反映出這些專業腫瘤解決方案的普及速度正在加快。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章：全球基因改造動物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品（基因槍、PCR、顯微注射等）
    • 按PCR類型（即時PCR、數位PCR系統等）
    • 依技術（DNA顯微注射、胚胎幹細胞介導的基因轉殖、逆轉錄病毒介導的基因轉殖等）
    • 依應用領域（重組人類蛋白、單株抗體、異種移植等）
    • 透過模式生物（小鼠、兔子、牛等）
    • 依最終用戶（生技/製藥公司、學術/研究機構、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美基因改造動物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲基因改造動物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區基因改造動物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲基因改造動物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲基因改造動物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球基因改造動物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • CH Boehringer Sohn Ko. KG
  • ELIAS Animal Health, LLC
  • Zoetis Inc.
  • AB Science SA
  • Karyopharm Therapeutics, Inc.
  • Vivesto AB
  • Merial Inc.
  • Elanco Animal Health, Inc.
  • Dechra Pharmaceuticals PLC
  • Torigen Pharmaceuticals Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 12982

The Global Transgenic Animal Market is projected to expand from USD 4.18 Billion in 2025 to USD 7.63 Billion by 2031, reflecting a compound annual growth rate of 10.55%. This industry involves the commercialization and use of organisms with deliberately altered genetic material to express specific, desirable traits for research or bioproduction. Key factors propelling this expansion include the growing need for predictive animal models to investigate chronic human ailments and the increasing demand for recombinant proteins and monoclonal antibodies within the biopharmaceutical field. Additionally, continuous improvements in gene-editing technologies act as a critical growth engine, allowing for the precise creation of animals that replicate complex physiological states essential for robust drug discovery and development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.18 Billion
Market Size 2031USD 7.63 Billion
CAGR 2026-203110.55%
Fastest Growing SegmentGene Gun
Largest MarketNorth America

Despite these positive drivers, the market faces substantial hurdles due to strict ethical regulations and rising public concern over animal welfare, which can delay regulatory approvals and heighten compliance expenses. Nonetheless, the scientific community continues to rely heavily on these models for essential research. Data from Understanding Animal Research in 2024 indicated that 45% of all regulated scientific procedures in Great Britain were specifically dedicated to creating or breeding genetically altered animals, highlighting the enduring and critical volume of this segment in biomedical innovation.

Market Driver

Breakthroughs in Genome Editing and Engineering Technologies serve as the primary catalyst for the Global Transgenic Animal Market. The integration of high-precision tools, such as CRISPR-Cas9, has revolutionized the capability to engineer animals with specific genetic modifications, enabling the development of organisms with human-compatible organs or precise disease phenotypes. This technological maturation has drawn significant investment, particularly for xenotransplantation applications where genetically modified pigs act as viable organ donors. For instance, eGenesis announced in September 2024 that it secured $191 million in Series D financing to advance its genetically engineered porcine kidney candidate into first-in-human clinical trials, demonstrating strong commercial confidence in these genomic platforms.

Concurrently, the market is significantly bolstered by the escalating demand for predictive preclinical human disease models. With the rise of complex chronic conditions, pharmaceutical developers require sophisticated in vivo systems to screen potential therapies and prevent late-stage clinical failures. In January 2024, the American Cancer Society's "Cancer Facts & Figures 2024" report projected that new cancer cases in the United States would surpass 2 million for the first time, emphasizing the urgent need for advanced oncology models. This disease burden drives massive capital allocation toward discovery pipelines utilizing transgenic organisms; illustrating this scale, Merck & Co. reported a total research and development expenditure of $30.5 billion for the full year 2023 in February 2024, reflecting the immense financial support for biomedical innovation.

Market Challenge

A major obstacle to the Global Transgenic Animal Market's growth is the presence of rigorous ethical regulations and increasing public scrutiny concerning animal welfare. Regulatory bodies worldwide are implementing stricter standards, compelling organizations to undergo exhaustive ethical reviews and strictly adhere to the principles of Replacement, Reduction, and Refinement. These compliance requirements demand significant investment in oversight and documentation, which extends development timelines and raises operational costs, ultimately discouraging the expansion of animal-based research and incentivizing the adoption of non-animal alternative methodologies.

The tangible impact of these restrictions is evident in recent operational data showing a contraction in the utilization of transgenic models. According to Understanding Animal Research, the number of procedures involving the creation and breeding of genetically altered animals in Great Britain decreased by 0.5% in 2024 compared to the previous year. This decline underscores the correlation between intensifying regulatory pressures and the dampening of market activities, as research institutions and pharmaceutical companies are forced to limit their reliance on these complex biological models due to the mounting ethical and administrative burdens.

Market Trends

A fundamental shift reshaping the transgenic animal market is the strategic outsourcing of model generation to Contract Research Organizations. Pharmaceutical firms are increasingly divesting from capital-intensive in-house breeding programs to mitigate the high fixed costs associated with facility maintenance and regulatory compliance. This transition allows drug developers to convert fixed overheads into variable costs while accessing specialized colonies that require complex husbandry. The financial impact of this operational shift is visible in the recent performance of key service providers; Charles River Laboratories reported in November 2024 that revenue for its Research Models and Services segment rose by 5.9% to $197.8 million in its third-quarter results, indicating a growing industry reliance on external partners.

Simultaneously, the market is witnessing a surge in the development of humanized immuno-oncology models specifically designed to evaluate complex immunotherapies. Unlike traditional transgenic organisms, these specialized platforms are engineered to host functional human immune systems, enabling researchers to test the efficacy of checkpoint inhibitors and antibody-drug conjugates in a systemic environment. This trend is distinct from general disease modeling as it focuses on the precise reconstitution of human immunological responses within the animal host to reduce translational failure rates. The commercial expansion of this niche is substantiated by companies like Champions Oncology, which reported a 17% revenue increase to $13.5 million in its fiscal 2025 second-quarter results in December 2024, reflecting the intensifying uptake of these specialized oncology solutions.

Key Market Players

  • C.H. Boehringer Sohn Ko. KG
  • ELIAS Animal Health, LLC
  • Zoetis Inc.
  • AB Science S.A.
  • Karyopharm Therapeutics, Inc.
  • Vivesto AB
  • Merial Inc.
  • Elanco Animal Health, Inc.
  • Dechra Pharmaceuticals PLC
  • Torigen Pharmaceuticals Inc

Report Scope

In this report, the Global Transgenic Animal Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Transgenic Animal Market, By Product

  • Gene Gun
  • PCR
  • Microinjections
  • Others

Transgenic Animal Market, By PCR

  • Real-Time PCR
  • Digital PCR Systems
  • Others

Transgenic Animal Market, By Technique

  • DNA Microinjection
  • Embryonic Stem Cell-Mediated Gene Transfer
  • Retrovirus-Mediated Gene Transfer
  • Others

Transgenic Animal Market, By Application

  • Recombinant Human Proteins
  • Monoclonal Antibodies
  • Xenotransplantation
  • Others

Transgenic Animal Market, By Model Organisms

  • Mice
  • Rabbit
  • Cow
  • Others

Transgenic Animal Market, By End User

  • Biotechnology & Pharmaceutical Companies
  • Academic & Research Organizations
  • Others

Transgenic Animal Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Transgenic Animal Market.

Available Customizations:

Global Transgenic Animal Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Transgenic Animal Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Gene Gun, PCR, Microinjections, Others)
    • 5.2.2. By PCR (Real-Time PCR, Digital PCR Systems, Others)
    • 5.2.3. By Technique (DNA Microinjection, Embryonic Stem Cell-Mediated Gene Transfer, Retrovirus-Mediated Gene Transfer, Others)
    • 5.2.4. By Application (Recombinant Human Proteins, Monoclonal Antibodies, Xenotransplantation, Others)
    • 5.2.5. By Model Organisms (Mice, Rabbit, Cow, Others)
    • 5.2.6. By End User (Biotechnology & Pharmaceutical Companies, Academic & Research Organizations, Others)
    • 5.2.7. By Region
    • 5.2.8. By Company (2025)
  • 5.3. Market Map

6. North America Transgenic Animal Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By PCR
    • 6.2.3. By Technique
    • 6.2.4. By Application
    • 6.2.5. By Model Organisms
    • 6.2.6. By End User
    • 6.2.7. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Transgenic Animal Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By PCR
        • 6.3.1.2.3. By Technique
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By Model Organisms
        • 6.3.1.2.6. By End User
    • 6.3.2. Canada Transgenic Animal Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By PCR
        • 6.3.2.2.3. By Technique
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By Model Organisms
        • 6.3.2.2.6. By End User
    • 6.3.3. Mexico Transgenic Animal Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By PCR
        • 6.3.3.2.3. By Technique
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By Model Organisms
        • 6.3.3.2.6. By End User

7. Europe Transgenic Animal Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By PCR
    • 7.2.3. By Technique
    • 7.2.4. By Application
    • 7.2.5. By Model Organisms
    • 7.2.6. By End User
    • 7.2.7. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Transgenic Animal Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By PCR
        • 7.3.1.2.3. By Technique
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By Model Organisms
        • 7.3.1.2.6. By End User
    • 7.3.2. France Transgenic Animal Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By PCR
        • 7.3.2.2.3. By Technique
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By Model Organisms
        • 7.3.2.2.6. By End User
    • 7.3.3. United Kingdom Transgenic Animal Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By PCR
        • 7.3.3.2.3. By Technique
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By Model Organisms
        • 7.3.3.2.6. By End User
    • 7.3.4. Italy Transgenic Animal Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By PCR
        • 7.3.4.2.3. By Technique
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By Model Organisms
        • 7.3.4.2.6. By End User
    • 7.3.5. Spain Transgenic Animal Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By PCR
        • 7.3.5.2.3. By Technique
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By Model Organisms
        • 7.3.5.2.6. By End User

8. Asia Pacific Transgenic Animal Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By PCR
    • 8.2.3. By Technique
    • 8.2.4. By Application
    • 8.2.5. By Model Organisms
    • 8.2.6. By End User
    • 8.2.7. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Transgenic Animal Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By PCR
        • 8.3.1.2.3. By Technique
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By Model Organisms
        • 8.3.1.2.6. By End User
    • 8.3.2. India Transgenic Animal Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By PCR
        • 8.3.2.2.3. By Technique
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By Model Organisms
        • 8.3.2.2.6. By End User
    • 8.3.3. Japan Transgenic Animal Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By PCR
        • 8.3.3.2.3. By Technique
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By Model Organisms
        • 8.3.3.2.6. By End User
    • 8.3.4. South Korea Transgenic Animal Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By PCR
        • 8.3.4.2.3. By Technique
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By Model Organisms
        • 8.3.4.2.6. By End User
    • 8.3.5. Australia Transgenic Animal Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By PCR
        • 8.3.5.2.3. By Technique
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By Model Organisms
        • 8.3.5.2.6. By End User

9. Middle East & Africa Transgenic Animal Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By PCR
    • 9.2.3. By Technique
    • 9.2.4. By Application
    • 9.2.5. By Model Organisms
    • 9.2.6. By End User
    • 9.2.7. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Transgenic Animal Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By PCR
        • 9.3.1.2.3. By Technique
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By Model Organisms
        • 9.3.1.2.6. By End User
    • 9.3.2. UAE Transgenic Animal Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By PCR
        • 9.3.2.2.3. By Technique
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By Model Organisms
        • 9.3.2.2.6. By End User
    • 9.3.3. South Africa Transgenic Animal Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By PCR
        • 9.3.3.2.3. By Technique
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By Model Organisms
        • 9.3.3.2.6. By End User

10. South America Transgenic Animal Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By PCR
    • 10.2.3. By Technique
    • 10.2.4. By Application
    • 10.2.5. By Model Organisms
    • 10.2.6. By End User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Transgenic Animal Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By PCR
        • 10.3.1.2.3. By Technique
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By Model Organisms
        • 10.3.1.2.6. By End User
    • 10.3.2. Colombia Transgenic Animal Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By PCR
        • 10.3.2.2.3. By Technique
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By Model Organisms
        • 10.3.2.2.6. By End User
    • 10.3.3. Argentina Transgenic Animal Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By PCR
        • 10.3.3.2.3. By Technique
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By Model Organisms
        • 10.3.3.2.6. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Transgenic Animal Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. C.H. Boehringer Sohn Ko. KG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. ELIAS Animal Health, LLC
  • 15.3. Zoetis Inc.
  • 15.4. AB Science S.A.
  • 15.5. Karyopharm Therapeutics, Inc.
  • 15.6. Vivesto AB
  • 15.7. Merial Inc.
  • 15.8. Elanco Animal Health, Inc.
  • 15.9. Dechra Pharmaceuticals PLC
  • 15.10. Torigen Pharmaceuticals Inc

16. Strategic Recommendations

17. About Us & Disclaimer